Addition of atezolizumab to capecitabine + bevacizumab is not clinically beneficial in the treatment of refractory metastatic colorectal cancer
Physician's Weekly,
1. Atezolizumab plus capecitabine + bevacizumab performed marginally better with regards to progression free survival in…